| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:EC0489
CAS:1096702-14-5
Package:25mg
|
| Company Name: |
Adooq Bioscience LLC
|
| Tel: |
400-025-6535 |
| Email: |
sales@adooq.cn |
| Products Intro: |
Product Name:EC0489
CAS:1096702-14-5
|
|
| Product Name: | EC0489 | | Synonyms: | EC0489;Vincaleukoblastin-23-oic acid, O4-deacetyl-, 2-[(2-mercaptoethoxy)carbonyl]hydrazide, disulfide with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-γ-glutamyl-N-(1-deoxy-D-glucitol-1-yl)-L-glutaminyl-L-α-glutamyl-N-(1-deoxy-D-glucitol-1-yl)-L-glutaminyl-L-α-glutamyl-N-(1-deox... | | CAS: | 1096702-14-5 | | MF: | C111H156N22O43S2 | | MW: | 2550.7 | | EINECS: | | | Product Categories: | | | Mol File: | 1096702-14-5.mol |  |
| | EC0489 Chemical Properties |
| density | 1.66±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | EC0489 Usage And Synthesis |
| Description | EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor[1]. Small molecule-drug conjugate (SMDC)[2]. The affinity of EC0489 toward the folate receptor (FR) is approximately half of that of folic acid (relative affinity 0.50)[1].FR-positive KB cells are highly sensitive to EC0489 with an IC50 of 5 nM[1]. EC0489 has a favorable toxicology profile in Rats. EC0489 (2, 3, and 4 μmol/kg) has antitumor activity against mice KB tumor models in a dose-dependent manner[1]. | | Uses | EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor[1]. Small molecule-agent conjugate (SMDC)[2]. | | in vivo | EC0489 has a favorable toxicology profile in Rats. EC0489 (2, 3, and 4 μmol/kg) has antitumor activity against mice KB tumor models in a dose-dependent manner[1]. | | References | [1]. Leamon CP, et al. Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications. J Pharmacol Exp Ther. 2011 Feb;336(2):336-43. [2]. Zhuang C, et al. Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment. Eur J Med Chem. 2019 Feb 1;163:883-895. |
| | EC0489 Preparation Products And Raw materials |
|